Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.72 |
| ▸ | ESR1 | P03372 | 5/20 | 0.72 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754116 | 0.94 | ESR1 (0.72) | ESR2ESR1NR1H2ABHD6HDAC6 | |
| SCHEMBL1641841 | 0.94 | ESR1 (0.72) | ESR2ESR1NR1H2ABHD6HDAC6 | |
| Hydrochloric Acid SCHEMBL1639774 | 0.93 | ESR1 (0.70) | ESR2ESR1NR1H2ABHD6HDAC6 | |
| SCHEMBL373718 | 0.91 | ESR1 (0.58) | ESR2ESR1NR1H2ABHD6HDAC6 | |
| SCHEMBL5913288 | 0.88 | ESR1 (0.54) | ESR2ESR1NR1H2ABHD6HDAC6 | |
| SCHEMBL29986831 | 0.88 | ESR1 (0.54) | ESR2ESR1NR1H2ABHD6HDAC6 | |
| SCHEMBL3353692 | 0.86 | ESR1 (0.60) | ESR2ESR1NR1H2ABHD6HDAC6 | |
| SCHEMBL6962549 | 0.85 | HDAC6 (0.65) | ESR2ESR1NR1H2HDAC6HDAC8 | |
| SCHEMBL8176145 | 0.84 | ESR2 (1.00) | ESR2ESR1ABHD6HDAC6HDAC8 | |
| SCHEMBL25206226 | 0.82 | ESR2 (0.76) | ESR2ESR1ABHD6HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015340-A1 | COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2026-01-15 | — | — | US | disclosed |
| WO-2025063645-A1 | NOVEL COMPOUND HAVING INHIBITORY ACTIVITY AGAINST HPK1 AND MLK3, AND ANTICANCER COMPOSITION CONTAINING SAME | (주)엠디바이오팜 | 2025-03-27 | — | — | WO | disclosed |
| EP-4520757-A1 | COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023214772-A1 | COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | 한국화학연구원 | 2023-11-09 | — | — | WO | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| WO-2018208132-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-11-15 | — | — | WO | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1869010-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | BTK, SYK, LCK | ESR2 4806/4885ESR1 4753/4885NR1H2 4809/4885 |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | TFPI, SERPINC1, SERPINE1 | ESR2 3298/4885ESR1 4202/4885NR1H2 3160/4885 |
| US-20260015340-A1 | COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | MINK1, HK1, PDK3 | ESR2 4253/4885ESR1 4614/4885NR1H2 459/4885 |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | ESR2 4460/4885ESR1 4638/4885NR1H2 2592/4885 |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | BTK, SYK, LCK | ESR2 4806/4885ESR1 4753/4885NR1H2 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.